Author

Meixing Chen

Observed name: M. Chen

Institution: Hubei Normal University

Observed institutions: Sun Yat-sen University, Zunyi Medical University, Sun Yat-sen University Cancer Center, Hubei Normal University, State Key Laboratory of Oncology in South China

ORCID: 0000-0002-4607-1440

Observed ORCID: 0000-0002-4607-1440

OpenAlex ID: A5085346570

1289P Pooled efficacy and safety from 2 pivotal phase II trials of taletrectinib in patients (Pts) with advanced or metastatic ROS1+ non-small cell lung cancer (NSCLC)

2024 · M. Pérol, W. Li, et al. · Annals of Oncology · 7

[18F]FDG PET/CT versus [18F]FDG PET/MRI in the diagnosis of lymph node metastasis in nasopharyngeal carcinoma: a systematic review and meta-analysis

2024 · Junfang Lei, Xu Li, et al. · Frontiers in Medicine · 4

Organophosphine-mediated formal [4 + 2] cycloadditions of benzo[c][1,2]dithiol-3-ones and iso(thio)cyanates via S to C-N skeletal editing strategy

2026 · Lingqian Wan, Bohao Zhang, et al. · Molecular Diversity · 2

LBA2: Taletrectinib vs crizotinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC): A matching-adjusted indirect comparison (MAIC)

2025 · M. Nagasaka, G. Liu, et al. · Journal of Thoracic Oncology · 2

53P Characterization of the safety profile of taletrectinib in patients with advanced ROS1+ non-small cell lung cancer (NSCLC): Results from TRUST-I and TRUST-II

2026 · Y.Y. Elamin, S. Owen, et al. · ESMO Open · 1

Treatment patterns and clinical outcomes for patients with hepatocellular carcinoma from China: a sub-analysis of the Global Hepatocellular Carcinoma BRIDGE Study

2017 · M. Chen, L. Li, et al. · Journal of Hepatology · 1

637P Taletrectinib vs repotrectinib in ROS1-positive (ROS1+) non–small cell lung cancer (NSCLC): A matching-adjusted indirect comparison (MAIC)

2024 · M. Nagasaka, G. Liu, et al. · Annals of Oncology

139P Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial

2024 · Y. Pan, L. Xu, et al. · Immuno-Oncology Technology

Overestimation of Contralateral Hilar Lymph Node Metastasis in Non-Metastatic Non-Small Cell Lung Cancer and Its Predictive Model: HAM

2024 · Z. Hou, B. Dong, et al. · International Journal of Radiation Oncology*Biology*Physics

970P Comparing clinical outcomes between PD-1 and PD-L1 inhibitors plus bevacizumab combined with hepatic arterial interventional therapies in unresectable hepatocellular carcinoma: A single-center, real-world study

2024 · Y. Pan, Z. Yuan, et al. · Annals of Oncology

198P Comparing clinical outcomes between PD-1 and PD-L1 inhibitors plus bevacizumab combined with hepatic arterial interventional therapies in unresectable hepatocellular carcinoma: A single-center, real-world study

2024 · Z. Yuan, Y. Pan, et al. · Annals of Oncology

Works count: 11

Citation count: 17

H-index: 2

I10-index: